EchoGo® Heart Failure vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 75/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
These two tools are highly comparable in their underlying technology and operational model, both being FDA-cleared AI platforms from Ultromics that analyze echocardiogram video clips. However, they target distinct cardiac conditions: EchoGo® Heart Failure focuses on detecting HFpEF, while EchoGo Amyloidosis is designed for the early detection of cardiac amyloidosis. Therefore, a healthcare provider would select the appropriate tool based on the specific diagnostic need for the patient.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGou00ae Heart Failure is an AI platform that analyzes routine echocardiograms to detect Heart Failure with preserved Ejection Fraction (HFpEF). EchoGou00ae Amyloidosis is an AI-powered screening tool that analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis (CA).
EchoGou00ae Heart Failure has been clinically validated with 90% sensitivity and 86% specificity for HFpEF detection. EchoGou00ae Amyloidosis demonstrates high diagnostic accuracy with 85% sensitivity and 93% specificity for identifying suspected cardiac amyloidosis.
EchoGou00ae Heart Failure is reimbursable via CPT code 0932T for outpatient analysis, with a national Medicare average of $316 per analysis. EchoGou00ae Amyloidosis has separate reimbursement: for inpatient use, NTAP Code ICD-10 XXE2X19 covers $1,000 per analysis, and for outpatient use, HCPCS Code C9786 (Clinical APC Code 574) covers $285 per analysis. Both are covered by Medicare and select commercial insurers.
Both EchoGou00ae Heart Failure and EchoGou00ae Amyloidosis are designed for seamless integration with existing clinical workflows and IT infrastructure, including DICOM for report delivery to PACS. EchoGou00ae Amyloidosis also specifically mentions HL7 integration.
EchoGou00ae Heart Failure delivers insights within 20 minutes to support clinical decisions. The description for EchoGou00ae Amyloidosis does not specify a turnaround time for its diagnostic output.
EchoGou00ae Heart Failure explicitly states that data export is available. While EchoGou00ae Amyloidosis emphasizes seamless integration with IT infrastructure, it does not explicitly mention a data export feature in its description.